Free Trial

NeoGenomics Q2 2023 Earnings Report

NeoGenomics logo
$9.58 -0.41 (-4.10%)
As of 03/3/2025 04:00 PM Eastern

NeoGenomics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

NeoGenomics Revenue Results

Actual Revenue
$146.92 million
Expected Revenue
$138.22 million
Beat/Miss
Beat by +$8.70 million
YoY Revenue Growth
N/A

NeoGenomics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

NeoGenomics Earnings Headlines

NeoGenomics: Decent Fundamentals, But Still Overvalued
Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
Piper Sandler Remains a Buy on NeoGenomics (NEO)
NeoGenomics price target lowered to $18 from $21 at Piper Sandler
BTIG Sticks to Their Buy Rating for NeoGenomics (NEO)
See More NeoGenomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NeoGenomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeoGenomics and other key companies, straight to your email.

About NeoGenomics

NeoGenomics (NASDAQ:NEO) operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

View NeoGenomics Profile

More Earnings Resources from MarketBeat